Dave joined Pappas Capital in 2002 as a member of our Scientific Advisory Board, becoming a Venture Advisor in 2012. He regularly provides clinical development guidance to our portfolio companies – including CoLucid Pharmaceuticals, Milestone Pharmaceuticals and Lumena Pharmaceuticals, for which he was a member of the board of directors prior to its acquisition by Shire in 2014.
Dave was most recently Senior Vice President of Development Operations for Xenoport. Prior to Xenoport, he co-founded NDA Partners, a drug development consulting company. Prior to NDA Partners, he was Chief Scientific Officer for Cardinal Health, and before that, Senior Vice President for Drug Development at Guilford Pharmaceuticals. He held senior level positions in drug development and regulatory affairs at Glaxo and Glaxo Wellcome, including Vice President for North American Regulatory Affairs. Prior to Glaxo, Dave held positions with Warner Lambert Corporation, Boehringer Ingelheim and Riker Laboratories. Dave served on the North Carolina State University School of Physical and Mathematical Science Foundation Board, and the University of Maryland School of Pharmacy Advisory Committee. He previously served as a director for Panacos Pharmaceuticals, a Pappas Ventures I portfolio company.
Massachusetts College of Pharmacy (BS)
University of Maryland School of Pharmacy (MS and PhD in Pharmaceutics)